Agios Pharmaceuticals, Inc.
Financials
Valuation Metrics
Agios Pharmaceuticals, Inc.'s Market Cap is $1.78B. At end of 2025 it was $1.59B. Ranked #2041 of 3,118 in US market (top 65%), #775 of 1,474 on NASDAQ (top 53%), #143 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 54%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.78B | US#2,041/3,118 Sec#143/265 |
| Revenue | $98M | US#2,677/3,118 Sec#125/265 |
| Net Income | $-411M | US—/3,118 Sec—/265 |
| Total Assets | $1.11B | US#2,418/3,118 Sec#95/265 |
| Net Assets | $1.03B | US#1,737/3,118 Sec#62/265 |
| Employees | 540 | US#2,238/3,118 Sec#78/265 |
| Value | ||
| P/B | 1.74x | US#1,111/3,118 Sec#50/265 |
| P/S | 18.11x | US#2,840/3,118 Sec#141/265 |
| FCF Yield | -20.51% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROE | -40.09% | US#2,624/3,118 Sec#138/265 |
| ROA | -37.11% | US#2,926/3,118 Sec#181/265 |
| Op. Margin | -466.78% | US#2,779/3,118 Sec#152/265 |
| Revenue Growth | 140.58% | US#68/3,118 Sec#25/265 |
| Earnings Growth | -163.27% | US#1,910/3,118 Sec#60/265 |
| Financial Health | ||
| Debt Ratio | 8.03% | US#78/3,118 Sec#37/265 |
| Total Debt | $31M | US#2,676/3,118 Sec#173/265 |
| FCF | $-365M | US#2,867/3,118 Sec#243/265 |
| Cash | $100M | US#2,229/3,118 Sec#173/265 |
| Current Ratio | 10.22x | US#236/3,118 Sec#75/265 |
| Performance | ||
| 1Y Return | -30.74% | US#2,584/3,118 Sec#208/265 |
| 1M Return | -5.82% | US#2,366/3,118 Sec#170/265 |
| From 52W High | -34.89% | US#2,106/3,118 Sec#141/265 |
| 1Y MDD | -50.89% | US#2,432/3,118 Sec#167/265 |
| Trading | ||
| Volume | 1,515,940 shares | US#718/3,118 Sec#58/265 |
| Trading Value | $46M | US#961/3,118 Sec#54/265 |
| Per Share | ||
| EPS | $-6.92 | US—/3,118 Sec—/265 |
| BPS | $17.25 | US#1,390/3,118 Sec#39/265 |
Company Info
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.